List view / Grid view

Anti-Cancer Therapeutics

Close-up of hand of child with leukaemia receiving chemotherapy

Drug combination an alternative leukaemia treatment to chemotherapy

12 November 2021 | By Anna Begley (European Pharmaceutical Review)

A clinical trial found that all-trans retinoic acid and arsenic trioxide is an effective treatment for acute promyelocytic leukaemia.

news

Actimab-A CLAG-M combination displays 100 percent remission rate

4 November 2021 | By Anna Begley (European Pharmaceutical Review)

Actinium's Actimab-A CLAG-M combination showed a 100 percent remission rate in relapsed or refractory acute myeloid leukaemia patients receiving 0.75 μCi/kg in Phase I study.

Microscopic view of renal cell carcinoma

news

Serial radiation therapy an effective alternative for kidney cancer

28 October 2021 | By Anna Begley (European Pharmaceutical Review)

The single-arm study showed that radiation therapy is an effective noninvasive alternative treatment for renal cell carcinoma (RCC).

Blue Antibody drug conjugate with four drug compounds linked to IgG immunoglobulin

news

SEC-MS: a “powerful tool” for ADC analysis, find researchers

27 October 2021 | By Hannah Balfour (European Pharmaceutical Review)

Research shows size exclusion chromatography (SEC) with mass spectrometry (MS) enables the simple, quick and reliable analysis of antibody-drug conjugates (ADCs).

news

NICE does not recommend tucatinib in new draft guidance

26 October 2021 | By Anna Begley (European Pharmaceutical Review)

The UK regulator concluded that breast cancer patients taking tucatinib live longer, but it is unclear how long for and whether it is cost effective.

news

Opdivo^® approved in Europe to treat a range of cancers

22 October 2021 | By Anna Begley (European Pharmaceutical Review)

Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.

Red and white blood cells in bloodstream, with too many white blood cells indicating leukaemia

news

Interferon treatment reduces leukaemia recurrence by 20 percent

21 October 2021 | By Anna Begley (European Pharmaceutical Review)

Interferon treatment with a bone marrow transplant bolstered outcomes for patients with advanced, high-risk leukaemia.

Hepatocellular carcinoma under microscope

news

Imfinzi^™ improves liver cancer survival in Phase III trial

15 October 2021 | By Anna Begley (European Pharmaceutical Review)

Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.

news

FDA awards 11 grants for rare disease treatment developments

15 October 2021 | By Anna Begley (European Pharmaceutical Review)

The FDA has awarded 11 grants equating to about $25 million of funding to clinical trials for the development of rare disease treatments.

news

Ultrasound delivers antibody therapy for HER2-positive brain metastasis

14 October 2021 | By Anna Begley (European Pharmaceutical Review)

MR-guided focused ultrasound safely delivered antibody therapy to breast cancer that has metastasised to the brain in Phase I study.

news

Lumakras^™ displays positive results in Phase Ib cancer study

8 October 2021 | By Anna Begley (European Pharmaceutical Review)

Lumakras™ (sotorasib) demonstrated effective response rates against non-small cell lung cancer and colorectal cancer in Phase Ib trial.

article

Merck’s Keytruda^®: update on trials and outcomes

8 October 2021 | By Anna Begley (European Pharmaceutical Review)

EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.

Different colour cancer ribbons next to stethoscope

article

Enhertu HER2-directed cancer treatment: key trials and results

1 October 2021 | By Anna Begley (European Pharmaceutical Review)

EPR's Anna Begley reviews some of the latest results for AstraZeneca’s Enhertu (trastuzumab deruxtecan) HER2-directed cancer therapy.

news

First patient dosed with BioNTech’s mRNA-based immunotherapy

1 October 2021 | By Anna Begley (European Pharmaceutical Review)

BioNTech expands clinical oncology portfolio with first patient dosed in Phase II trial of mRNA-based vaccine for colorectal cancer.

news

Radionuclide therapy a promising option to treat HER2 breast cancer

30 September 2021 | By Anna Begley (European Pharmaceutical Review)

The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Anti-Cancer Therapeutics